2.6 - 2.78
1.51 - 7
Join Discuss about BCEL with like-minded investors
hmmm that BCEL
119 Replies 10 👍 12 🔥
@Hatta2021 #LWT Trading
liked the vid. any chance you can do one on BCEL and some other pharma's?
52 Replies 9 👍 11 🔥
Next Dividend Date
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as its lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients.
CEO: John Orwin
HQ: 450 East Jamie Court South San Francisco, 94080 California